Biologic
UniProt Q9NPF7
Risankizumab
Skyrizi
- Mechanism of action
- IL-23 antagonist (mAb)
- In plain language
- A lab-made antibody that neutralizes IL-23, an inflammation-driving protein linked to psoriasis and Crohn's disease.
- How it works
- Risankizumab is a humanized IgG1 monoclonal antibody that selectively binds the p19 subunit of interleukin-23, preventing IL-23 from engaging its cell-surface receptor. By blocking this interaction, the antibody interrupts downstream signaling that drives differentiation and maintenance of Th17 and other IL-23-responsive immune cells, suppressing production of pro-inflammatory mediators implicated in psoriasis, psoriatic arthritis, and inflammatory bowel disease.
- Therapeutic applications
- FDA-approved for moderate-to-severe plaque psoriasis and active psoriatic arthritis in patients 6 and older, and for moderately to severely active Crohn's disease and ulcerative colitis in adults.
- Class
- Monoclonal antibody
- Therapeutic area
- Immunology
View
Related compounds